Symbols

SRTS

Sensus Healthcare·NASDAQ

--(--)

SRTS fundamentals

SRTS Q4 2025 Earnings

Sensus Healthcare (SRTS) released its earnings on Feb 12, 2026: revenue was 4.94M (YoY -62.20%), missed estimates; EPS was -0.19 (YoY -311.11%), missed estimates.

Revenue / YoY

4.94M

-62.20%

EPS / YoY

-0.19

-311.11%

Report date

Feb 12, 2026

SRTS Earnings Call Summary for Q4,2025

CPT Code Breakthrough: Exclusive reimbursement codes enable noninvasive skin cancer treatment, diversifying revenue and reducing customer concentration risk.
Q1 2026 Growth: Shipments expected to exceed Q4 2025, driven by direct sales and international expansion (China, Brazil).
Financial Strength: $22M cash, no debt; targeting 2026 full-year profitability with disciplined cost control.
FDA Program Success: 2025 utilization up 8x, with customers converting to outright purchases post-reimbursement clarity.
Risk Note: Largest customer exclusion from 2026 projections; TDI regulatory timeline uncertain.

Earnings

EPS

Revenue

Revenue & Expenses

SRTS has released its 2025 Q4 earnings report, with revenue of 4.94M, reflecting a YoY change of -62.20%, and net profit of -3.17M, showing a YoY change of -304.85%. The Sankey diagram below clearly presents SRTS's revenue sources and cost distribution.

Key Indicators

Sensus Healthcare (SRTS) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Sensus Healthcare (SRTS)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Sensus Healthcare (SRTS)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Sensus Healthcare (SRTS)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown